Digital Therapeutics in the Management of Opioid Use Disorder: A Systematic Review of Emerging Technologies and Clinical Outcomes

Priyanka Katru; Renu Sharma; Anita Sharma

doi:10.21760/jaims.10.5.16

Priyanka Katru Ph.D. Scholar, Department of Agad Tantra, National Institute of Ayurveda, Deemed to be University, Jaipur, Rajasthan, India. https://orcid.org/0000-0002-5917-8570
Renu Sharma Ph.D. Scholar, Department of Agad Tantra, National Institute of Ayurveda, Deemed to be University, Jaipur, Rajasthan, India. https://orcid.org/0000-0002-8194-0007
Anita Sharma Professor & HOD, Department of Agad Tantra, National Institute of Ayurveda, Deemed to be University, Jaipur, Rajasthan, India. https://orcid.org/0000-0002-7069-8614

DOI: https://doi.org/10.21760/jaims.10.5.16

Keywords: Digital health, Opioid Addiction, Telepsychiatry, CBT Apps, reSET-O, AI in addiction, mHealth, Digital Interventions

Abstract

Opioid use disorder (OUD) poses a major global health burden, with limited access to traditional treatment in many regions. Digital therapeutics (DTx) offer, noble tools to support treatment, enhance accessibility, and improve outcomes. The objective of the study is to systematically review the current evidence on the effectiveness, implementation, and outcomes of DTx in the management of OUD. A thorough literature was searched using PubMed, Science direct, Google scholar et cetera, from 2015 to 2024, which included randomize control trials (RCTs), systemic reviews, and real-world studies evaluating digital interventions (apps, telehealth, AI based tools, wearable for OUD. A total of 28 studies met the inclusion criteria. digital interventions demonstrated improved treatment, retention, opioid abstinence, and patient engagement. Tools such as reset-O, telehealth, CBT based mobile apps and AI driven systems showed efficacy in both clinical and real-world settings. Barriers included digital, illiteracy, privacy, concerns, and Limited regulatory frameworks, especially in low- and middle-income countries. Digital therapeutics present a promising adjunct or alternative to conventional OUD treatment. Tailored implementation, Cultural Adaptation, and regulatory support are essential for maximizing their impact.

Downloads

Download data is not yet available.

References

United Nations Office on Drugs and Crime. World Drug Report 2023. Vienna: United Nations; 2023 [cited 2025 Jan 10]. Available from: https://www.unodc.org/unodc/en/data-and-analysis/world-drug-report-2023.html.

Marsch LA, Campbell A, Campbell C, Chen C-H, Ertin E, Ghitza U, et al. The application of digital health to the assessment and treatment of substance use disorders: The past, current, and future role of the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat. 2020;112 Suppl 1:4–11 [cited 2025 Jan 10]. Available from: https://ubiwell.io/public/papers/marsch-ctn-role.pdf.

Maricich YA, Xiong X, Gerwien R, Kuo A, Velez F, Imbert B, et al. Real-world evidence for a prescription digital therapeutic to treat opioid use disorder. Curr Med Res Opin. 2021;37(2):175–83. doi:10.1080/03007995.2020.1846023.

Monico LB, Eastlick M, Michero D, Pielsticker P, Glasner S. Feasibility and acceptability of a novel digital therapeutic combining behavioral and pharmacological treatment for opioid use disorder. Digit Health. 2024;10:20552076241258400. doi:10.1177/20552076241258400.

Christensen DR, Landes RD, Jackson L, Marsch LA, Mancino MJ, Chopra MP, et al. Adding an Internet-delivered treatment to an efficacious treatment package for opioid dependence. J Consult Clin Psychol. 2014;82(6):964–72. doi:10.1037/a0037496.

Pham H, Lin C, Zhu Y, Clingan SE, Lin LA, Mooney LJ, et al. Telemedicine-delivered treatment for substance use disorder: A scoping review. J Telemed Telecare. 2025;31(3):359–75. doi:10.1177/1357633X231190945.

Ghosh A, Kale A, Laxmi R, Naik SS, Subodh BN, Basu D. Breaking barriers: Assessing the feasibility and acceptability of telemedicine-assisted buprenorphine induction for opioid use disorder in India. Indian J Psychiatry. 2024;66(10):956–62. doi:10.4103/indianjpsychiatry.indianjpsychiatry_432_24.

Shi JM, Henry SP, Dwy SL, Orazietti SA, Carroll KM. Randomized pilot trial of Web-based cognitive-behavioral therapy adapted for use in office-based buprenorphine maintenance. Subst Abuse. 2019;40(2):132–5. doi:10.1080/08897077.2019.1569192.

Sigmon SC, Peck KR, Batchelder SR, Badger GJ, Heil SH, Higgins ST. Technology-assisted buprenorphine treatment in rural and nonrural settings: Two randomized clinical trials. JAMA Netw Open. 2023;6(9):e2331910. doi:10.1001/jamanetworkopen.2023.31910.

Tofighi B, Badiei B, Badolato R, Lewis CF, Nunes E, Thomas A, Lee JD. Integrating text messaging in a low-threshold telebuprenorphine program for New York City residents with opioid use disorder during COVID-19: A pilot randomized controlled trial. J Addict Med. 2023;17(5):e281–e286. doi:10.1097/ADM.0000000000001161.

Kiburi SK, Paruk S, Kwobah EK, Chiliza B. Exploring user experiences of a text message-delivered intervention among individuals on opioid use disorder treatment in Kenya: A qualitative study. PLOS Digit Health. 2023;2(11):e0000375. doi:10.1371/journal.pdig.0000375.

Liang D, Han H, Du J, Zhao M, Hser YI. A pilot study of a smartphone application supporting recovery from drug addiction. J Subst Abuse Treat. 2018;88:51–8. doi:10.1016/j.jsat.2018.02.006.

King VL, Brooner RK, Peirce JM, Kolodner K, Kidorf MS. A randomized trial of Web-based videoconferencing for substance abuse counseling. J Subst Abuse Treat. 2014;46(1):36–42. doi:10.1016/j.jsat.2013.08.009.

Marsch LA. Digital therapeutics in the treatment of opioid and stimulant use disorders [Internet]. 2021 [cited 2025 Apr 7]. Available from: https://heal.nih.gov/files/2021-07/digital-therapeutics-treatment-opioid-marsch.pdf.

Kiburi SK, Ngarachu E, Tomita A, Paruk S, Chiliza B. Digital interventions for opioid use disorder treatment: A systematic review of randomized controlled trials. J Subst Abuse Treat. 2022;144:108926. doi:10.1016/j.jsat.2022.108926.

Aronowitz SV, Zucker N, Thompson M, James R, Clapp J, Mandell D. Patient and provider experiences with opioid use disorder care delivered via telehealth: A systematic mixed-studies review. Drug Alcohol Depend. 2025;266:112522. doi:10.1016/j.drugalcdep.2024.112522.

Ward MK, Guille C, Jafry A, Gwanzura T, Pryce K, Lewis P, Brady KT. Digital health interventions to support women with opioid use disorder: A scoping review. Drug Alcohol Depend. 2024;261:111352. doi:10.1016/j.drugalcdep.2024.111352.

Lyzwinski L, Elgendi M, Menon C. Users' acceptability and perceived efficacy of mHealth for opioid use disorder: Scoping review. JMIR Mhealth Uhealth. 2024;12:e49751. doi:10.2196/49751.

Lin LA, Casteel D, Shigekawa E, Weyrich MS, Roby DH, McMenamin SB. Telemedicine-delivered treatment interventions for substance use disorders: A systematic review. J Subst Abuse Treat. 2019;101:38–49. doi:10.1016/j.jsat.2019.03.007.

Tice JA, Whittington MD, Campbell JD, Pearson SD. The effectiveness and value of digital health technologies as an adjunct to medication-assisted therapy for opioid use disorder. J Manag Care Spec Pharm. 2021;27(4):528–32. doi:10.18553/jmcp.2021.27.4.528.

Miller-Rosales C, Morden NE, Brunette MF, Busch SH, Torous JB, Meara ER. Provision of digital health technologies for opioid use disorder treatment by US health care organizations. JAMA Netw Open. 2023;6(7):e2323741. doi:10.1001/jamanetworkopen.2023.23741.

Eibl JK, Gauthier G, Pellegrini D, Daiter J, Varenbut M, Hogenbirk JC, Marsh DC. The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting. Drug Alcohol Depend. 2017;176:133–8. doi:10.1016/j.drugalcdep.2017.01.048.

Hammerslag LR, Mack A, Chandler RK, Fanucchi LC, Feaster DJ, LaRochelle MR, et al. Telemedicine buprenorphine initiation and retention in opioid use disorder treatment for Medicaid enrollees. JAMA Netw Open. 2023;6(10):e2336914. doi:10.1001/jamanetworkopen.2023.36914.

Lira MC, Jimes C, Coffey MJ. Retention in telehealth treatment for opioid use disorder among rural populations: A retrospective cohort study. Telemed J E Health. 2023;29(12):1890–6. doi:10.1089/tmj.2023.0044.

Marino EN, Karns-Wright T, Perez MC, Potter JS. Smartphone app-based contingency management and opioid use disorder treatment outcomes. JAMA Netw Open. 2024;7(12):e2448405. doi:10.1001/jamanetworkopen.2024.48405.

Velez FF, Anastassopoulos KP, Colman S, et al. Reduced healthcare resource utilization in patients with opioid use disorder in the 12 months after initiation of a prescription digital therapeutic. Adv Ther. 2022;39:4131–45. doi:10.1007/s12325-022-02217-y.

Ganesh R, Rao R, Deb KS, Bhad R, Yadav D. Digital capacity and interest in mHealth interventions among individuals on opioid agonist maintenance treatment: A cross-sectional community-based study. Indian J Psychol Med. 2022;44(4):354–8. doi:10.1177/02537176211027239.

Kiburi SK, Kwobah EK, Paruk S, et al. Feasibility, acceptability, and preliminary efficacy of a cognitive behavior therapy text-message intervention among individuals with opioid use disorder in Kenya: A randomized feasibility trial. BMC Digit Health. 2023;1:14. doi:10.1186/s44247-023-00014-3.

Xu X, Chen S, Chen J, et al. Feasibility and preliminary efficacy of a community-based addiction rehabilitation electronic system in substance use disorder: Pilot randomized controlled trial. JMIR Mhealth Uhealth. 2021;9(4):e21087. doi:10.2196/21087. Available from: https://mhealth.jmir.org/2021/4/e21087.

Le UTN, Tran TT, Le GT, et al. Effectiveness of text message reminders and motivational interviews on adherence to methadone treatment in Vietnam: A randomized controlled trial. J Public Health (Oxf). 2025;fdaf009. doi:10.1093/pubmed/fdaf009.

Maricich YA, Bickel WK, Marsch LA, et al. Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for treatment of opioid use disorder. Curr Med Res Opin. 2021;37(2):167–73. doi:10.1080/03007995.2020.1846022.

Buresh M, Stern R, Rastegar D. Treatment of opioid use disorder in primary care. BMJ. 2021;373:n784. Available from: https://internetbookofemergencymedicine.com/wp-content/uploads/2021/08/treatment-of-opioid-use-disorder-in-primary-care.pdf.

Sawyer-Morris G, Wilde JA, Molfenter T, et al. Use of digital health and digital therapeutics to treat substance use disorder in criminal justice settings: A review. Curr Addict Rep. 2024;11:149–62. doi:10.1007/s40429-023-00523-1.

Donnell A, Unnithan C, Tyndall J, Hanna F. Digital interventions to save lives from the opioid crisis prior and during the SARS COVID-19 pandemic: A scoping review of Australian and Canadian experiences. Front Public Health. 2022;10:900733. doi:10.3389/fpubh.2022.900733.